Clinical trial NCT06953596: Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder
Official title: Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder: A Single-centre, Single-arm, Open-label Phase I/II Proof-of-concept and Feasibility Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Prolonged Grief Disorder
Complicated Grief
Keywords: Neuromodulation
Repetitive Transcranial Magnetic Stimulation
Bereavement
Proof-of-Concept
Feasibility
Intermittent Theta Burst Stimulation (iTBS)
Lead sponsor: Bruyere Research Institute
Sponsor class: OTHER
First posted: 2025-05-01
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single-centre, single-arm, open-label phase I/II proof-of-concept and feasibility clinical trial
Primary purpose: TREATMENT

Brief summary: Grief is a normal response after the death of a loved one. With time, the grief response decreases and people learn to cope with their loss. However, for some, the response becomes more intense and distressing. This is called prolonged grief disorder (PGD). People with PGD experience emotional pain and a deep longing for their loved one. PGD normally occurs \<10% of people after a loss, but it has become more common since the COVID-19 pandemic (\~30%). If left untreated, PGD leads to poor quality of life and increased risk of death. Treatment options such as medication and therapy are available; however, they can cause negative side effects and take a long time to work. To help individuals with PGD, we need treatments that work well and quickly.

Repetitive transcranial magnetic stimulation (rTMS) is a safe, non-invasive treatment that delivers magnetic pulses to brain areas responsible for mood. rTMS has been approved in Canada to treat mood disorders. There is research to show that rTMS is safe and well-tolerated, and that works well in treating Post-Traumatic Stress Disorder (PTSD), a condition with similar symptoms to PGD. To determine whether rTMS is effective for treating PGD, we first need to determine if rTMS as a treatment for PGD is safe and feasible among grieving individuals.

Detailed description: Prolonged Grief Disorder (PGD) is an important challenge among bereaved individuals. While the grief response following loss is typically acute, with symptoms diminishing over time, it can sometimes lead to prolonged grief disorder (PGD). PGD is characterized by persistent longing and preoccupation with the decedent, emotional pain, as well as cognitive and functional impairment that persists for more than 6 months after a loss. Prevalence rates for PGD vary; systematic reviews show pooled prevalence rates of 10% after death due to natural causes, but rising as high as 49% after death due to sudden or violent causes (e.g., suicide, homicide, mass casualty event). We found that the incidence of PGD in the COVID-19 pandemic rose to \~30% of bereaved family members, regardless of the cause of death (COVID-19 or other illness), and that the prevalence remained unchanged more than 18 months post-loss. PGD is also more common among women, people with severe pre-loss grief or depressive symptoms, those who have lost a child, and those with structural vulnerability (e.g. lower education level and income). Recently, PGD was included as a diagnostic entity in the International Classification of Diseases (ICD), and the Diagnostic and Statistical Manual of Mental Disorders (DSM).

PGD is associated with serious physical and mental health problems, including increased incidence of cardiovascular events, sleep disturbances, substance abuse, and suicidal ideation, resulting in poor overall quality of life and increased risk of mortality. Alongside the physical and psychological symptoms of bereavement, there is a concomitant increase in healthcare utilization, contributing to increased healthcare expenditure. PGD has been associated with increased emergency department visits, general hospital admissions, psychiatric hospitalizations, general practitioner, psychiatrist, and psychologist visits, as well as use of medications such as antidepressants and anxiolytics. Studies have shown that bereaved individuals have increased healthcare expenditures compared to non-bereaved controls, and widowed individuals spend 40% more on healthcare during the first 2-years post-death compared with pre-death expenditures. Moreover, bereaved individuals are less economically productive, particularly when they have PGD. In response to the accumulating evidence showing the wide-reaching consequences of PGD, several organizations (e.g., Canadian Grief Alliance, Canadian Virtual Hospice), are calling for the development and implementation of a national grief strategy to address this "hidden and urgent public health crisis."

Existing treatment options for PGD are limited. Pharmacotherapies such as antidepressants (e.g., tricyclic antidepressants, selective serotonin reuptake inhibitors) are often prescribed for PGD, though their efficacy for grief-related symptoms is minimal, and time to effect and side effects (e.g., headaches, dry mouth, insomnia, flashbacks, palpitations) are barriers to uptake. Psychotherapy (including Complicated Grief Therapy) has shown moderate effectiveness in symptom reduction in a small number of trials, but issues with homogenous (e.g., primarily Western countries) and small samples and variable inclusion criteria raise questions about the generalizability of the evidence. Additionally, psychotherapy is resource-intensive and time-consuming with delayed effectiveness. There is an acute need for feasible, effective, and scalable treatment options to respond to PGD.

Repetitive Transcranial Magnetic Stimulation (rTMS) may be a feasible and efficacious treatment for PGD. rTMS is a safe, tolerable, and non-invasive brain stimulation technique approved by Health Canada in 2002 for the treatment of major depression, post-traumatic stress disorder (PTSD), and other mood and anxiety disorders. Using an inductor coil placed against the scalp, rTMS employs powerful, focused magnetic pulses to induce an electrical current that depolarizes the underlying neuronal tissue and causes action potentials which, depending on the stimulation parameters (high-frequency vs. low-frequency), increase or decrease cortical excitability. When administered repetitively, TMS can cause long-term neuromodulation and subsequent therapeutic benefit.

rTMS is effective for treating post-traumatic stress disorder (PTSD). To date, over 15 studies (10 RCTs) have demonstrated safety, tolerability, efficacy, and durability for treating PTSD with high- and low-frequency rTMS stimulation at different sites (e.g., right dorsolateral prefrontal cortex (DLPFC), left DLPFC, and medial prefrontal cortex).Notably, one open-label case series reported \>50% improvement in PTSD symptoms in 57% of patients following rTMS to the dorsomedial prefrontal cortex. However, rTMS has never been evaluated for the treatment of PGD. Clinically, experiences associated with PGD (i.e., trauma associated with the dying and grief experience) and its symptoms are similar to PTSD, with several overlapping characteristics (e.g., intrusive thoughts or images, avoidance, emotional numbness), raising the question of whether rTMS may be efficacious for treating PGD too.

Objective:

To determine if accelerated rTMS is a safe and feasible treatment for PGD among bereaved individuals. The secondary objective is to examine the preliminary efficacy of accelerated rTMS for treatment of PGD.

Sample Size:

As the main objective of this study is to demonstrate safety and feasibility, no formal sample size calculation was performed. The goal of this study is to provide estimates, along with margins of error, of the enrollment rate and efficacy outcomes to inform a subsequent sham-controlled clinical trial.

Statistical Analysis:

Analysis of safety and feasibility outcomes will be descriptive, with point estimates and 95% confidence intervals. The efficacy analysis will follow an intent-to-treat approach. We will compare the proportion of participants with a minimal clinically important difference in secondary efficacy outcomes at 2-week follow-up.

Details of Eligibility, Intervention Protocol, and Outcome Measures are provided elsewhere.

Eligibility criteria: Inclusion Criteria:

1. Bereaved individuals \>/= 18 years of age
2. Score \>25 on the Inventory of Complicated Grief
3. Must have a primary care physician
4. Ability to understand and communicate in English
5. Ability to provide first-person informed consent

Exclusion Criteria:

1. Current or previously diagnosed seizure disorder
2. Documented brain lesions
3. Contraindications to TMS (i.e., metallic skull plates, clips, stimulators, pacemakers)
4. Current substance abuse disorder (e.g., schizophrenia)
5. Pregnancy or lactation, or trying to conceive
6. Advanced, incurable illness with an expected prognosis of \<3 months - bereaved family members are known to be at elevated risk of death from medical illness, but if death is expected in the near future, it would be difficult to justify using an entire week of their limited time for an unproven therapy.

Primary outcomes:
measure: Recruitment Rate
timeFrame: Through study completion, up to 9 months
measure: Enrollment Rate
timeFrame: Through study completion, up to 9 months
measure: Intervention Completion Rate
timeFrame: Through study completion, up to 10 months
measure: Withdrawal Rate
timeFrame: Through study completion, up to 16 months
measure: Follow-up Completion Rate
timeFrame: Through study completion, up to 16 months
measure: Number of Participants with Adverse Events
timeFrame: Through intervention completion, up to 1 week
Secondary outcomes:
measure: Prolonged Grief Disorder - Global Impression of Change
timeFrame: Day 5 (last day of intervention), 2-week follow-up, 4-week follow-up, and monthly thereafter for up to 6 months
measure: Change in Prolonged Grief
timeFrame: Baseline, day 5 (last day of intervention), 2-week follow-up, 4-week follow-up, and monthly thereafter for up to 6 months
measure: Prolonged Grief - Change in Post-Traumatic Stress
timeFrame: Baseline, day 5 (last day of intervention), 2-week follow-up, 4-week follow-up, and monthly thereafter for up to 6 months
measure: Prolonged Grief - Change in Depression
timeFrame: Baseline, day 5 (last day of intervention), 2-week follow-up, 4-week follow-up, and monthly thereafter for up to 6 months
measure: Prolonged Grief - Change in Work and Social Functioning
timeFrame: Baseline, day 5 (last day of intervention), 2-week follow-up, 4-week follow-up, and monthly thereafter for up to 6 months
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Bruyere Health
state: Ontario
Study officials:
References:
citation: Prigerson HG, Bierhals AJ, Kasl SV, Reynolds CF 3rd, Shear MK, Day N, Beery LC, Newsom JT, Jacobs S. Traumatic grief as a risk factor for mental and physical morbidity. Am J Psychiatry. 1997 May;154(5):616-23. doi: 10.1176/ajp.154.5.616.
citation: Szuhany KL, Malgaroli M, Miron CD, Simon NM. Prolonged Grief Disorder: Course, Diagnosis, Assessment, and Treatment. Focus (Am Psychiatr Publ). 2021 Jun;19(2):161-172. doi: 10.1176/appi.focus.20200052. Epub 2021 Jun 17.
citation: Buur C, Zachariae R, Komischke-Konnerup KB, Marello MM, Schierff LH, O'Connor M. Risk factors for prolonged grief symptoms: A systematic review and meta-analysis. Clin Psychol Rev. 2024 Feb;107:102375. doi: 10.1016/j.cpr.2023.102375. Epub 2023 Dec 29.
citation: Lapenskie J, Anderson K, Lawlor PG, Kabir M, Noel C, Heidinger B, Parsons HA, Cohen L, Gratton V, Besserer E, Adeli S, Murphy R, Warmels G, Bruni A, Bhimji K, Dyason C, Enright P, Desjardins I, Wooller K, Arsenault-Mehta K, Webber C, Bedard D, Iyengar A, Bush SH, Isenberg SR, Tanuseputro P, Vanderspank-Wright B, Downar J. Long-term bereavement outcomes in family members of those who died in acute care hospitals before and during the first wave of COVID-19: A cohort study. Palliat Med. 2024 Feb;38(2):264-271. doi: 10.1177/02692163231223394. Epub 2024 Jan 16.
citation: Downar J, Parsons HA, Cohen L, Besserer E, Adeli S, Gratton V, Murphy R, Warmels G, Bruni A, Bhimji K, Dyason C, Enright P, Desjardins I, Wooller K, Kabir M, Noel C, Heidinger B, Anderson K, Arsenault-Mehta K, Lapenskie J, Webber C, Bedard D, Iyengar A, Bush SH, Isenberg SR, Tanuseputro P, Vanderspank-Wright B, Lawlor P. Bereavement outcomes in family members of those who died in acute care hospitals before and during the first wave of COVID-19: A cohort study. Palliat Med. 2022 Sep;36(8):1305-1312. doi: 10.1177/02692163221109711. Epub 2022 Jul 4.
citation: Djelantik AAAMJ, Smid GE, Mroz A, Kleber RJ, Boelen PA. The prevalence of prolonged grief disorder in bereaved individuals following unnatural losses: Systematic review and meta regression analysis. J Affect Disord. 2020 Mar 15;265:146-156. doi: 10.1016/j.jad.2020.01.034. Epub 2020 Jan 13.
citation: Lundorff M, Holmgren H, Zachariae R, Farver-Vestergaard I, O'Connor M. Prevalence of prolonged grief disorder in adult bereavement: A systematic review and meta-analysis. J Affect Disord. 2017 Apr 1;212:138-149. doi: 10.1016/j.jad.2017.01.030. Epub 2017 Jan 23.
citation: Kentish-Barnes N, Prigerson HG. Is this bereaved relative at risk of prolonged grief? Intensive Care Med. 2016 Aug;42(8):1279-81. doi: 10.1007/s00134-015-4182-6. Epub 2015 Dec 23. No abstract available.
citation: Lenferink LIM, van den Munckhof MJA, de Keijser J, Boelen PA. DSM-5-TR prolonged grief disorder and DSM-5 posttraumatic stress disorder are related, yet distinct: confirmatory factor analyses in traumatically bereaved people. Eur J Psychotraumatol. 2021 Dec 9;12(1):1-14. doi: 10.1080/20008198.2021.2000131. eCollection 2021.
citation: Shear MK, Simon N, Wall M, Zisook S, Neimeyer R, Duan N, Reynolds C, Lebowitz B, Sung S, Ghesquiere A, Gorscak B, Clayton P, Ito M, Nakajima S, Konishi T, Melhem N, Meert K, Schiff M, O'Connor MF, First M, Sareen J, Bolton J, Skritskaya N, Mancini AD, Keshaviah A. Complicated grief and related bereavement issues for DSM-5. Depress Anxiety. 2011 Feb;28(2):103-17. doi: 10.1002/da.20780.
citation: Tang S, Xiang Z. Who suffered most after deaths due to COVID-19? Prevalence and correlates of prolonged grief disorder in COVID-19 related bereaved adults. Global Health. 2021 Feb 11;17(1):19. doi: 10.1186/s12992-021-00669-5.
citation: Prigerson HG, Kakarala S, Gang J, Maciejewski PK. History and Status of Prolonged Grief Disorder as a Psychiatric Diagnosis. Annu Rev Clin Psychol. 2021 May 7;17:109-126. doi: 10.1146/annurev-clinpsy-081219-093600. Epub 2021 Feb 1.